Le Lézard
Classified in: Health
Subject: FDA

Health Canada Cleared EmeTerm Anti-Nausea Wristband and HeadaTerm Anti-Migraine Head Patch


VANCOUVER, British Columbia, July 2, 2018 /PRNewswire/ -- Shortly after WAT Medical's leading product to treat nausea-induced vomiting, EmeTerm, received its FDA clearance earlier in April, it has now also received official clearance from Health Canada. Health Canada ensures all of its certified medical products are of the highest quality and are able to provide the best care for patients to improve their lives. WAT Medical has reached the long-awaited milestone and is thrilled to introduce its innovative technology to Canada. The product is effective for a wide range of treatments, including all types of motion sickness induced by travelling and morning sickness. EmeTerm allows its users to be free from medication side effects like dizziness, drowsiness and thickened lung secretions.

EmeTerm's technology is called neuro modulation, which is Health Canada cleared and clinically proven. The electric current is sent by the peripheral nervous system via P6 acupuncture point on the underside of the wrist. The electric pulses are delivered to their targets in the brain and precisely block the emesis signals from brain to stomach. EmeTerm is currently used by consumers in over 20 counties worldwide, including all of Europe, the United States, and Australia.

EmeTerm is the winner of 2017 iF Design Award for its innovative design and usability. The patented electrodes design enhances the transfer of electric pulses from device to skin. No conduct gel is needed, which increases convenience and affordability to consumers. 

WAT Medical's anti-migraine device, HeadaTerm, also received Health Canada clearance, and is going to enter the Canadian market along with EmeTerm. HeadaTerm also uses neuromodulation by sending precise electric impulse to targeted area in the brain responsible for endorphin release. HeadaTerm reduces migraine pain within minutes after it occurs, and also works as an effective preventative measure by reducing the frequency and intensity of migraine episodes.

Unlike any anti-migraine technology before it, HeadaTerm is a disposable device at an affordable price. Its small and lightweight design allows it to be extremely portable, offering consumers fast and convenient migraine treatment.

WAT Medical will be attending FIME 2018, Florida International Medical Expo, the largest medical trade fair across America, on July 17-19 (Booth No.: BQ 85). Both EmeTerm and HeadaTerm will be featured.

For more information, please visit WAT Medical Enterprise Ltd.'s website at www.watmedical.com  

Contact: [email protected]

SOURCE WAT Medical Enterprise Ltd.


These press releases may also interest you

at 02:05
AstraZeneca: Revenue and EPS summary     Q1 2024 % Change $m Actual CER1 - Product Sales 12,177 15 18 - Alliance Revenue   457 59 59...

at 02:00
Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at...

at 02:00
In response to the increasing complexities of the aging journey and the rising trend of...

at 02:00
PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that it has entered into a target-exclusive research and...

at 02:00
Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood...

at 01:24
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...



News published on and distributed by: